SURPASS-2 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Archive — April 2024
Page 4 of 5 of this archive, newest first.
Ireland pharmacy body issues counselling standards for semaglutide initiation
The evidence base is thin and the document says so, which is to its credit.
Sarcopenia is a diagnosis, not a synonym for losing lean mass
The gap between a defensible recommendation and a confident one is where most of the harm in this subject lives.
The supply gap as a clinical event
Cost is the modal reason for discontinuation in every dataset we have seen, and it is absent from the clinical literature.
The three-times-upper-limit convention, and where it came from
Asymptomatic pancreatic enzyme elevation is common on treatment and is not pancreatitis. The distinction is clinical, not biochemical.
Spain pharmacy body issues counselling standards for semaglutide initiation
The evidence base is thin and the document says so, which is to its credit.
What a 13% rise in coupling-reagent prices does to a 15 mg vial
Follow the resin, not the catalogue.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
How a release document is put together in a regulated plant
Nothing on this page is difficult. It is simply unfamiliar, and unfamiliarity is what makes a weak certificate look like a strong one.
The advice is mostly reasonable. The certainty is not earned.
Grading six widely repeated claims against the studies actually behind them.
The 28-day notice: how a compounding wind-down works in Brazil
The document is four pages. Three of them are about dates.
Wuhan export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
South Africa health authority warns on falsified liraglutide pens
Reported from the analysis, not from a warning notice.
Calder Vale Peptides of Skipton enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
Thiamine and the vomiting patient
Which markers are informative, which are confounded, and which move for reasons unrelated to nutrition.
What changed at MKM in April, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
SURPASS-3 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
From the floor in Shenzhen: 19 posters, one theme
Reported from the sessions, and from the two hours afterwards.
Matrix, laser, needle: the plumbing that determines what you see
A brief and unromantic tour of the interface between a liquid sample and a vacuum.
Why your endoscopist wants to know about your injection
This is the single interaction with ordinary medical care that patients most need to disclose, and it is the one most often not asked about.
What the sequence tells you about how a peptide will fail
The sequence predicts the failure mode. A methionine predicts oxidation; an asparagine followed by a glycine predicts deamidation; a cysteine predicts disulphide scrambling.
Spain pharmacy body issues counselling standards for liraglutide initiation
The evidence base is thin and the document says so, which is to its credit.
The quiet end of Calder Vale Peptides of Skipton
A proper account of an operation that existed, and of what closing it cost.
VendorInvestigate result on a Changsha dulaglutide lot lands 3.5 points below the supplier’s figure
A reminder that a purity figure is the output of a method, and that methods differ.
Equal area is not equal mass: the response factor problem
Peptide bonds absorb strongly near 214 nm; aromatic side chains absorb near 280 nm. A method reading at 280 is blind to any fragment lacking an aromatic residue.
Tolerability is the ceiling, and the ceiling is personal
The ceiling varies severalfold between people, and nothing measurable at baseline predicts where it sits.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
Halvard & Pike Apothecary of Portland, Maine closes after 19 years
A proper account of an operation that existed, and of what closing it cost.
Norway declines to reimburse liraglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
BCH declines, for the 6th time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
What the upper limit of normal for ALT should be, and why it is not
Estimated glomerular filtration rate is a calculation with muscle mass in the denominator of its assumptions. In this population that matters.
A tested vial is evidence about a vial
Every third-party report in this market describes a sample somebody chose to send. That choice is outside the laboratory’s control and outside its records.
Inspectors cite Calder Vale Peptides of Skipton over sterility assurance
The observation that closes a facility is rarely the dramatic one.
The 10-day notice: how a compounding wind-down works in Mexico
The document is four pages. Three of them are about dates.
Singapore caps tirzepatide prescribing to 11 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
SURMOUNT-OSA extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Same material, different gradients, different answers
The Journal submitted split samples from single lots to three assay services, under names unconnected to this publication, and published each method alongside each result.
Side effects, cost, supply, target: four reasons with four trajectories
Why the reason for stopping changes what happens afterwards.